Haloperidol Induced Orofacial Dyskinesia: Clinical Insights Into Buccolingual Masticatory Syndrome
Author(s) -
Bereda Gudisa
Publication year - 2025
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.71083
ABSTRACT Haloperidol and other antipsychotics can cause buccolingual masticatory syndrome (BLMS), a rare but serious extrapyramidal disorder characterized by involuntary movements of the cheeks, jaws, and tongue. The author describes a 40‐year‐old man presenting with retrograde lingual movements, chewing difficulties, and speech impairment after 2 years of haloperidol therapy for catatonic‐type schizophreniform disorder. Magnetic resonance imaging showed abnormal activity in the basal ganglia without structural lesions. Treatment with oral trihexyphenidyl hydrochloride, 5 mg daily, resulted in symptom resolution within 24 h. Haloperidol induces motor dysfunction by blocking dopamine D2 receptors in the basal ganglia. Haloperidol was discontinued, and the patient was transitioned to clozapine, a second‐generation antipsychotic with a lower risk of tardive dyskinesia. Clozapine was initiated at 12.5 mg daily and titrated to 50 mg daily over two weeks, following standard hematologic monitoring protocols. Early diagnosis and appropriate management, including medication adjustment and adjunctive therapy, are critical to optimizing outcomes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom